463,416 Shares in Caribou Biosciences, Inc. $CRBU Bought by GSA Capital Partners LLP

GSA Capital Partners LLP purchased a new position in Caribou Biosciences, Inc. (NASDAQ:CRBU) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 463,416 shares of the company’s stock, valued at approximately $816,000. GSA Capital Partners LLP owned approximately 0.47% of Caribou Biosciences as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. AQR Capital Management LLC boosted its stake in shares of Caribou Biosciences by 741.6% in the first quarter. AQR Capital Management LLC now owns 525,878 shares of the company’s stock worth $480,000 after acquiring an additional 463,391 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Caribou Biosciences during the first quarter worth about $61,000. Creative Planning bought a new stake in Caribou Biosciences during the 2nd quarter valued at approximately $25,000. XTX Topco Ltd bought a new stake in Caribou Biosciences during the 2nd quarter valued at approximately $133,000. Finally, Jane Street Group LLC raised its stake in Caribou Biosciences by 64.7% during the 2nd quarter. Jane Street Group LLC now owns 483,610 shares of the company’s stock valued at $609,000 after purchasing an additional 189,923 shares during the period. 77.51% of the stock is owned by institutional investors.

Caribou Biosciences Trading Down 0.6%

Shares of CRBU stock opened at $1.56 on Wednesday. The stock has a market capitalization of $154.72 million, a price-to-earnings ratio of -1.44 and a beta of 2.38. Caribou Biosciences, Inc. has a 12-month low of $1.38 and a 12-month high of $3.54. The stock’s 50-day moving average price is $1.67 and its 200-day moving average price is $1.84.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.08. Caribou Biosciences had a negative return on equity of 89.11% and a negative net margin of 1,030.42%.The company had revenue of $1.50 million during the quarter, compared to analyst estimates of $2.28 million. As a group, research analysts predict that Caribou Biosciences, Inc. will post -0.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CRBU has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a research note on Friday, July 17th. Bank of America reduced their price objective on shares of Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Finally, HC Wainwright boosted their target price on shares of Caribou Biosciences from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Caribou Biosciences has an average rating of “Moderate Buy” and an average price target of $7.75.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.